

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM456260

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
ANI PHARMACEUTICALS, INC.		12/29/2017	Corporation: DELAWARE
ANIP ACQUISITION COMPANY		12/29/2017	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	CITIZENS BANK, N.A., as Administrative Agent
<b>Street Address:</b>	28 State Street
<b>City:</b>	Boston
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02109
<b>Entity Type:</b>	National Banking Association: UNITED STATES

## PROPERTY NUMBERS Total: 18

Property Type	Number	Word Mark
Registration Number:	2160791	ATACAND
Registration Number:	2485478	ATACAND HCT
Registration Number:	1753552	ARIMIDEX
Registration Number:	3611359	ARIMIDEX
Registration Number:	3579173	A
Registration Number:	1574288	CASODEX
Registration Number:	3344593	CDX 50
Registration Number:	4988076	INNOPRAN XL
Registration Number:	4987989	INNOPRAN
Registration Number:	2585471	BIOSANTE
Registration Number:	1147470	LITHOBID
Registration Number:	0683928	VANCOCIN
Registration Number:	0788963	INDERAL
Registration Number:	1900307	INDERAL
Registration Number:	1255059	
Registration Number:	1154480	REGLAN
Registration Number:	0808375	CORTENEMA

OP \$465.00 2160791

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	1879493	FERGLUCON

**CORRESPONDENCE DATA**

**Fax Number:** 4045725100

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 4045723408

**Email:** mramic@kslaw.com

**Correspondent Name:** Mia Ramic King and Spalding

**Address Line 1:** 1180 Peachtree Street NE

**Address Line 4:** Atlanta, GEORGIA 30309

<b>ATTORNEY DOCKET NUMBER:</b>	18588.015277
<b>NAME OF SUBMITTER:</b>	/s/ Mia Ramic
<b>SIGNATURE:</b>	/s/ Mia Ramic
<b>DATE SIGNED:</b>	12/29/2017

**Total Attachments: 6**

source=ANI - Executed Trademark Security Agreement (2)#page1.tif

source=ANI - Executed Trademark Security Agreement (2)#page2.tif

source=ANI - Executed Trademark Security Agreement (2)#page3.tif

source=ANI - Executed Trademark Security Agreement (2)#page4.tif

source=ANI - Executed Trademark Security Agreement (2)#page5.tif

source=ANI - Executed Trademark Security Agreement (2)#page6.tif

NOTICE  
OF  
GRANT OF SECURITY INTEREST  
IN  
TRADEMARKS

United States Patent and Trademark Office

Ladies and Gentlemen:


Please be advised that (a) pursuant to the Security Agreement dated as of December 29, 2017 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Security Agreement”), by and among the Obligors party thereto (each an “Obligor” and collectively, the “Obligors”) and Citizens Bank, N.A., as Administrative Agent (the “Administrative Agent”) for the secured parties referenced therein (the “Secured Parties”), the undersigned Obligor has granted a continuing security interest in and continuing lien upon the trademarks, trademark licenses and trademark applications shown on Schedule 1 attached hereto (the “Trademarks”) to the Administrative Agent for the ratable benefit of the Secured Parties and (b) the undersigned hereby grants to the Administrative Agent, for the ratable benefit of the Secured Parties, a continuing security interest in, and a right to set off against, any and all right, title and interest of such Obligor in and to the Trademarks.

The Obligors and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the Trademarks (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any Trademark.


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Very truly yours,

ANI PHARMACEUTICALS, INC.,  
a Delaware corporation


By:   
Name: Stephen Carey  
Title: VP and CFO

ANIP ACQUISITION COMPANY,  
a Delaware corporation

By:   
Name: Stephen Carey  
Title: VP and CFO

Acknowledged and Accepted:

CITIZENS BANK, N.A.,  
as Administrative Agent


By:   
Name: Prasanna Manyem  
Title: Vice President

Schedule 1

TRADEMARKS

TRADEMARK	OWNER	APPLICATION NO.	APPLICATION DATE	REGISTRATION NO.	REGISTRATION DATE
ATACAND*	ASTRAZENECA AB	75033908	12/18/1995	2160791	5/26/1998
ATACAND HCT*	ASTRAZENECA AB	75250934	3/3/1997	2485478	9/4/2001
Arimidex*	ASTRAZENECA UK LIMITED	73794256	4/19/1989	1753552	4/28/2009
ARIMIDEX & LOGO*	ASTRAZENECA UK LIMITED	77455690	04/23/2008	3611359	4/28/2009
 ARIMIDEX LOGO (A WITH ARROW) *	ASTRAZENECA UK LIMITED	77455977	04/23/2008	3579173	2/24/2009
					
CASODEX*	ASTRAZENECA UK LIMITED d/b/a IPR PHARMACEUTICALS	73764741	11/21/1988	1574288	1/2/1990
CDX 50 & DESIGN- REPRESENTATION OF A TABLET*	ASTRAZENECA UK LIMITED	76413298	5/29/2002	3344593	11/27/2007
					

TRADEMARKS

TRADEMARK	OWNER	APPLICATION NO.	APPLICATION DATE	REGISTRATION NO.	REGISTRATION DATE
INNOPRAN XL	ANI PHARMACEUTICALS, INC.	86797512	10/23/2015	4988076	06/28/2016
INNOPRAN	ANI PHARMACEUTICALS, INC.	86792685	10/19/2015	4987989	6/28/2016
BIOSANTE	ANI PHARMACEUTICALS, INC.	78058343	4/13/2001	2585471	6/25/2002
LITHOBID	ANI PHARMACEUTICALS, INC.	73219510	6/13/1979	1147470	2/24/1981
VANGOCIN	ANI PHARMACEUTICALS, INC.	72064010	12/10/1958	0683928	8/25/1959
INDERAL **	ANI PHARMACEUTICALS, INC.	72189475	3/24/1964	0788963	5/4/1965
INDERAL **	ANI PHARMACEUTICALS, INC.	74534024	6/6/1994	1900307	6/20/1995
 ***	ANI PHARMACEUTICALS, INC.	73305742	4/13/1981	1255059	10/25/1983
REGLAN	ANIP ACQUISITION COMPANY	73231083	9/12/1979	1154480	5/19/1981

TRADEMARK

REEL: 006238 FRAME: 0914

TRADEMARKS					
TRADEMARK	OWNER	APPLICATION NO.	APPLICATION DATE	REGISTRATION NO.	REGISTRATION DATE
CORTNEMA	ANIP ACQUISITION COMPANY	72226791	8/30/1965	0808375	5/17/1966
FERGLUCON	ANIP ACQUISITION COMPANY d/b/a ANI PHARMACEUTICAL, INC.	74491487	1/24/1994	1879493	2/21/1995

**TRADEMARK**

\* Trademarks marked with \* are subject to royalty payments under the License Agreement dated December 29, 2017 between AstraZeneca AB, AstraZeneca UK Limited, and ANI Pharmaceuticals, Inc.

\*\* Trademarks marked with \*\* are subject to royalty payments under the Amended and Restated Royalty Agreement for Inderal® Products between AstarZeneca UK Limited and ANI Pharmaceuticals, Inc. (as successor by assignment to Cranford Pharmaceuticals, LLC), and solely for the purposes of Section 7.12, Akrimax Pharmaceuticals, LLC.